Increased METTL3 may ameliorate inflammation in RA patients by inhibiting nuclear factor kappa-B (NF-κB) signaling to suppress lipopolysaccharide (LPS)-induced expression of inflammatory cytokines Interleukin-6 (IL-6) and tumor necrosis factor alpha-α (TNF-a) in macrophages (44). This evidence concerns the gene TNF and rheumatoid arthritis.